Q4 2025 Celcuity Inc Earnings Call Transcript
Key Points
- Celcuity Inc (CELC) achieved significant clinical and regulatory milestones in 2025, including the FDA's acceptance of their new drug application for gedatolisib with a priority review.
- The Phase 3 VICTORIA-1 trial showed unprecedented efficacy data for gedatolisib, setting new benchmarks in HR-positive HER2-negative advanced breast cancer treatment.
- Gedatolisib demonstrated a favorable safety profile with mostly low-grade adverse events and no significant hypoglycemia issues, unlike other PI3K inhibitors.
- Celcuity Inc (CELC) has made substantial progress in preparing for the potential commercial launch of gedatolisib, including building a strong sales force and engaging with key healthcare decision-makers.
- The company has a strong financial position with $441.5 million in cash and investments, expected to finance operations through 2027.
- Celcuity Inc (CELC) reported a net loss of $177 million for the full year 2025, a significant increase from the previous year.
- Research and development expenses increased by $40.8 million in 2025, driven by employee and consulting expenses and commercial launch-related activities.
- General and administrative expenses rose significantly, primarily due to increased employee-related costs and noncash stock-based compensation.
- The company faces challenges in ensuring patient adherence to IV administration of gedatolisib, although they believe efficacy will drive adoption.
- There is uncertainty regarding the timing and details of the data release for the PIK3CA mutant cohort of the VICTORIA-1 trial, which could impact investor confidence.
Good afternoon, ladies and gentlemen, and welcome to the Celcuity fourth-quarter and full year 2025 financial call. (Operator Instructions)
I would now like to turn the conference over to Jodi Sievers, Corporate Communications and Investor Relations at Celcuity. Please go ahead.
Thank you, John, and good afternoon, everyone. Thank you for joining us to review Celcuity's fourth-quarter and full year 2025 financial results and business update.
Earlier today, Celcuity Inc. released financial results for the fourth quarter and full year ended December 31, 2025. The press release can be found on the Investors section of Celcuity's website.
Joining me on the call today are Brian Sullivan, Celcuity's Chief Executive Officer and Co-Founder; Vicki Hahne, Chief Financial Officer; as well as Igor Gorbatchevsky, Chief Medical Officer; and Eldon Mayer, Chief Commercial Officer, who will be available during Q&A.
Before we begin, I would like to remind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
